CAR-T Archives

Home CAR-T Page 9

Latest Posts

News and Trends 29 Aug 2017

Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks

European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’ main competitor to launch the first therapy. Yesterday, Gilead bought a $11.9Bn (€9.9Bn) ticket to enter…

August 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 6 Sep 2017

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Gilead has just splashed out $12 billion for Kite Pharma, and the FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR-T therapy. I sat down with Gregg…

September 6, 2017 - 6 minutesmins - By Evelyn Warner

News and Trends 7 Sep 2017

CAR-T is Nearly Here: How Will It Be Delivered?

As we anticipate the first-ever CAR-T therapy market approval we look at the important aspect of treatment delivery and viral vector strategies. Cell and gene therapy is increasingly coming into…

September 7, 2017 - 4 minutesmins - By External Contributor

News and Trends 16 Feb 2018

French Biotech Gets a CRISPR Patent for CAR-T Research

Update (16/02/2018): On top of the European patent it got last July, Cellectis now also has two US patents to use CRISPR technology to make CAR-T cells. Cellectis has said…

February 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Jul 2017

Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns

Editor's Note: Novartis did note a death from cerebral hemorrhage in its hearing with the FDA yesterday. With the application review hearing set for tomorrow, the FDA has shared its…

July 11, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 5 Jul 2017

Cutting Through the BS in Biopharma: How To Spot Hype

Faced with the oft-quoted figure that 90% of clinical trials end in failure, how can patients, investors, and readers be spared more disappointment? After discussing failures in biotech at Refresh earlier in…

July 5, 2017 - 4 minutesmins - By Evelyn Warner

servier transgene car t cells viral vector

News and Trends 29 Jun 2017

Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology

Transgene will help Servier develop new methods based on viral vectors to improve the precision of genetic modifications and the production of CAR-T cells. The French pharma Servier decided to…

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Cell Medica Catapult Therapy TCR Acquisition

News and Trends 21 Jun 2017

British Biotech Tops up its Cancer Pipeline with New TCR Therapy

Cell Medica just acquired Catapult Therapy TCR, set up by UK's CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it's all…

June 21, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 2 May 2017

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing "off-the-shelf" therapies, based on…

May 2, 2017 - 2 minutesmins - By Melanie De Almeida

In Depth 13 Mar 2018

The Most Important Battle in Gene Editing: CRISPR versus TALEN

Despite all the hype, CRISPR is still not in the clinic as a standalone therapy or part of another. So where is it in biotech? CRISPR needs no introduction. Since…

March 13, 2018 - 6 minutesmins - By Editorial Team

SIRION Biotech cell therapy lentivirus lentiboost

News and Trends 12 Apr 2017

Taking Cell Therapy one Step Further with this Boost Reagent

Cell therapy is revolutionizing medicine, here’s how the latest technology can help overcome the major challenges stopping it from taking over the market. Offering unprecedented possibilities to treat some of…

April 12, 2017 - 4 minutesmins - By External Contributor

David Sourdive Cellectis interview off the shelf cell therapy 1

Interview 16 Mar 2017

“In the Coming Decade, Off-the-Shelf Cell Therapy will Become a Reality”

David Sourdive, co-founder of Cellectis, discusses his pioneering work developing off-the-shelf CAR-T for cancer and the future directions of cell therapy. Last week I had the opportunity to attend the…

March 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering